Core Viewpoint - Baiyang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.04% and a total market value of 12.888 billion yuan, reflecting a mixed performance in the market [1]. Financial Performance - For the period from January to September 2025, Baiyang Pharmaceutical reported a revenue of 5.627 billion yuan, representing a year-on-year decrease of 8.41%. The net profit attributable to shareholders was 476 million yuan, down 25.67% compared to the previous year [2]. - The company has distributed a total of 1.551 billion yuan in dividends since its A-share listing, with 1.201 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Baiyang Pharmaceutical was 11,100, a decrease of 40.83% from the previous period. The average circulating shares per person increased by 68.99% to 47,194 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant, holding 2.9097 million shares, while ICBC Frontier Medical Stock A has exited the list [3]. Stock Performance - Baiyang Pharmaceutical's stock price has increased by 4.57% year-to-date, but has seen a decline of 6.63% over the last five trading days and 9.75% over the last twenty days [1].
百洋医药跌2.04%，成交额4345.69万元，主力资金净流出1343.17万元